Walleye Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Walleye Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-34,609	Closed	-$214K	–	1126
2020 Q1	$214K	Buy	+34,609	New	+$305K	0.05%	428

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Capital's AMAG Position: Q2 2020 in Review

Walleye Capital sold out of AMAG Pharmaceuticals (AMAG) in Q2 2020, closing a stake of 34,609 shares — an estimated $214K sold.

Walleye Capital first reported a position in AMAG in Q1 2020 and held it in 1 quarter. The position peaked at $214K in Q1 2020. 119 funds tracked by Wall St. Rank hold AMAG as of Q2 2020.

Walleye Capital reported no remaining AMAG Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Walleye Capital sold 34,609 AMAG Pharmaceuticals shares in Q2 2020, an estimated $214K.
Walleye Capital first reported a position in AMAG Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Walleye Capital's AMAG Pharmaceuticals position peaked at $214K in Q1 2020.
119 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2020.

Based on Walleye Capital's 13F filing for Q2 2020, filed 14 Aug 2020.